A Randomized, Double-blinded, Placebo-controlled, Crossover Trial to Assess the Effect of Orally Administered LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 23 Jul 2018
At a glance
- Drugs Licogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics; Proof of concept
- Sponsors Novartis
- 26 Jun 2018 Results from this and 2 more srudies, presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 06 Mar 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
- 07 Aug 2013 New trial record